Erratum: Clinicopathological correlates of adrenal Cushing's syndrome (J Clin Pathol (2015) 68 (175-186) DOI: 10.1136/jclinpath-2014-202612);Clinicopathological correlates of adrenal Cushing's syndrome

Journal of Clinical Pathology

Volumn 68, Issue 3, 2015, Pages 175-186

  Duan, Kai ^a,b   Hernandez, Karen Gomez ^a,c   Mete, Ozgur ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CORTICOTROPIN; CYCLIC AMP; CYCLIN DEPENDENT KINASE INHIBITOR 2A; G PROTEIN COUPLED RECEPTOR; HYDROCORTISONE; MELANOCORTIN 2 RECEPTOR; PROTEIN P53; RETINOBLASTOMA PROTEIN; SOMATOMEDIN B; STEROID HORMONE RECEPTOR BLOCKING AGENT; WNT PROTEIN; BIOLOGICAL MARKER;

ACTH SECRETING ADENOMA; ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL INCIDENTALOMA; ADRENALECTOMY; ALBRIGHT SYNDROME; ALGORITHM; ARMADILLO REPEAT CONTAINING 5 GENE; ARTICLE; BECKWITH WIEDEMANN SYNDROME; CARNEY COMPLEX; CELL PROLIFERATION; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; CROOKE CELL ADENOMA; CUSHING SYNDROME; DEXAMETHASONE SUPPRESSION TEST; DIFFUSE BILATERAL ADRENOCORTICAL HYPERPLASIA; DNA MICROARRAY; FACE DISORDER; FACIAL PLETHORA; GENE; GENE OVEREXPRESSION; GENOTYPE PHENOTYPE CORRELATION; GERMLINE MUTATION; GNAS GENE; GOLD STANDARD; GROWTH DISORDER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HISTOPATHOLOGY; HUMAN; HYDROCORTISONE RELEASE; HYPERCORTISOLISM; INFERIOR PETROSAL SINUS; INFERIOR PETROSAL SINUS SAMPLING; KIDNEY CANCER; LEIOMYOMATOSIS; MULTIPLE ENDOCRINE NEOPLASIA; MUSCLE WEAKNESS; NODULAR HYPERPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OSTEOPOROSIS; PATHOGENESIS; PATHOLOGY; PDE11A GENE; PDE8B GENE; PETROSAL SINUS SAMPLING; PRIORITY JOURNAL; PRKACA GENE; PRKAR1A GENE; PROGNOSIS; RETICULIN ALGORITHM; SCORING SYSTEM; SIGNAL TRANSDUCTION; SKIN ATROPHY; SOMATIC MUTATION; STRIA; WEIGHT GAIN; WEISS SCORING SYSTEM; WNT SIGNALING PATHWAY; ADRENAL GLAND; ADRENAL GLAND NEOPLASMS; BIOPSY; BLOOD; COMPLICATION; DIAGNOSTIC IMAGING; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PREDICTIVE VALUE; PROCEDURES; RISK FACTOR;

ADRENAL GLAND NEOPLASMS; ADRENAL GLANDS; ADRENALECTOMY; ADRENOCORTICOTROPIC HORMONE; BIOLOGICAL MARKERS; BIOPSY; CUSHING SYNDROME; DIAGNOSTIC IMAGING; HUMANS; HYDROCORTISONE; IMMUNOHISTOCHEMISTRY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 84923343749     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2014-202612corr1     Document Type: Erratum

References (105)

1. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93:1526-40.
2. Bertagna X, Guignat L, Groussin L, et al. Cushing's disease. Best Pract Res Clin Endocrinol Metab 2009;23:607-23.
3. Hatipoglu BA. Cushing's syndrome. J Surg Oncol 2012;106:565-71.
4. Newell-price J, Bertagna X, Grossman AB, et al. Cushing's syndrome. Lancet 2006;367:1605-17.
5. Tabarin A, Perez P. Pros and cons of screening for occult Cushing syndrome. Nat Rev Endocrinol 2011;7:445-55.
6. Stratakis CA. Cushing syndrome in pediatrics. Endocrinol Metab Clin North Am 2012;41:793-803.
7. Clayton RN, Raskauskiene D, Reulen RC, et al. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 2011;96:632-42.
8. Carroll TB, Findling JW. Cushing's syndrome of nonpituitary causes. Curr Opin Endocrinol Diabetes Obes 2009;16:308-15.
9. Bourdeau I, Lampron A, Costa MH, et al. Adrenocorticotropic hormone-independent Cushing's syndrome. Curr Opin Endocrinol Diabetes Obes 2007;14:219-25.
10. Shahani S, Nudelman RJ, Nalini R, et al. Ectopic corticotropin-releasing hormone (CRH) syndrome from metastatic small cell carcinoma: a case report and review of the literature. Diagn Pathol 2010;5:56.
11. Stratakis CA. Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin-independent Cushing syndrome). Endocr Dev 2008;13:117-32.
12. Stratakis CA, Boikos SA. Genetics of adrenal tumors associated with Cushing's syndrome: a new classification for bilateral adrenocortical hyperplasias. Nat Clin Pract Endocrinol Metab 2007;3:748-57.
13. De Venanzi A, Alencar GA, Bourdeau I, et al. Primary bilateral macronodular adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes 2014;21:177-84.
14. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2008;93:2454-62.
15. Tritos NA, Biller BM, Swearingen B. Management of Cushing disease. Nat Rev Endocrinol 2011;7:279-89.
16. Sasano H. The adrenal cortex. In: Stefaneanu L, Sasano H, Kovacs K, eds. Molecular and cellular endocrine pathology. London: Arnold, 2000:221-52.
17. Cizza G, Nieman LK, Doppman JL, et al. Factitious Cushing syndrome. J Clin Endocrinol Metab 1996;81:3573-7.
18. Newell-price J, Trainer P, Besser M, et al. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998;19:647-72.
19. Boscaro M, Arnaldi G. Approach to the patient with possible Cushing's syndrome. J Clin Endocrinol Metab 2009;94:3121-31.
20. Miller BS, Doherty GM. Surgical management of adrenocortical tumours. Nat Rev Endocrinol 2014;10:282-92.
21. Ilias I, Sahdev A, Reznek RH, et al. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer 2007;14:587-99.
22. Lattin GE, Sturgill ED, Tujo CA, et al. From the radiologic pathology archives: Adrenal tumors and tumor-like conditions in the adult: radiologic-pathologic correlation. Radiographics 2014;34:805-29.
23. Young WF. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 2007;356:601-10.
24. Rockall AG, Babar SA, Sohaib SA, et al. CT and MR imaging of the adrenal glands in ACTH-independent cushing syndrome. Radiographics 2004;24:435-52.
25. Powell AC, Stratakis CA, Patronas NJ, et al. Operative management of Cushing syndrome secondary to micronodular adrenal hyperplasia. Surgery 2008;143:750-8.
26. Courcoutsakis N, Prassopoulos P, Stratakis CA. CT findings of primary pigmented nodular adrenocortical disease: rare cause of ACTH-independent Cushing syndrome. AJR Am J Roentgenol 2010;194:W541.
27. Lacroix A. ACTH-independent macronodular adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009;23:245-59.
28. Duan K, Mete O. Clinicopathologic correlates of primary aldosteronism. Arch Pathol Lab Med. In press.
29. Zeiger MA, Thompson GB, Duh QY, et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations. Endocr Pract 2009;15:450-3.
30. Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol 2011;164:851-70.
31. Kannan S, Remer EM, Hamrahian AH. Evaluation of patients with adrenal incidentalomas. Curr Opin Endocrinol Diabetes Obes 2013;20:161-9.
32. Arnaldi G, Boscaro M. Adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab 2012;26:405-19.
33. Funder J, Carey R, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266-81.
34. Lack EE. AFIP atlas of tumor pathology, fourth series, fascicle 8. Tumors of the adrenal glands and extraadrenal paraganglia. Washington, DC: ARP Press, 2007.
35. Mcnicol AM. Diagnostic and molecular aspects of adrenal cortical tumors. Semin Diagn Pathol 2013;30:197-206.
36. Mcnicol AM. Update on tumours of the adrenal cortex, phaeochromocytoma and extra-adrenal paraganglioma. Histopathology 2011;58:155-68.
37. Mcnicol AM. Lesions of the adrenal cortex. Arch Pathol Lab Med 2008;132:1263-71.
38. Mcnicol AM. A diagnostic approach to adrenal cortical lesions. Endocr Pathol 2008;19:241-51.
39. Berthon A, Martinez A, Bertherat J, et al. Wnt/β-catenin signalling in adrenal physiology and tumour development. Mol Cell Endocrinol 2012;351:87-95.
40. Xekouki P, Azevedo M, Stratakis CA. Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways. Expert Rev Endocrinol Metab 2010;5:697-709.
41. Mete O, Asa SL. Clinicopathological correlations in pituitary adenomas. Brain Pathol 2012;22:443-53.
42. Mete O, Asa SL. Therapeutic implications of accurate classification of pituitary adenomas. Semin Diagn Pathol 2013;30:158-64.
43. Louiset E, Duparc C, Young J, et al. Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N Engl J Med 2013;369:2115-25.
44. Nishikawa T, Iwata M, Sasano H. Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N Engl J Med 2014;370:1071.
45. Lefebvre H, Duparc C, Chartrel N, et al. Intraadrenal adrenocorticotropin production in a case of bilateral macronodular adrenal hyperplasia causing Cushing's syndrome. J Clin Endocrinol Metab 2003;88:3035-42.
46. Mete O, Asa SL. Precursor lesions of endocrine system neoplasms. Pathology 2013;45:316-30.
47. Morin E, Mete O, Wasserman JD, et al. Carney complex with adrenal cortical carcinoma. J Clin Endocrinol Metab 2012;97:E202-6.
48. Carney JA, Libé R, Bertherat J, et al. Primary pigmented nodular adrenocortical disease: the original 4 cases revisited after 30 years for follow-up, new investigations, and molecular genetic findings. Am J Surg Pathol 2014;38:1266-73.
49. Almeida MQ, Stratakis CA. Carney complex and other conditions associated with micronodular adrenal hyperplasias. Best Pract Res Clin Endocrinol Metab 2010;24:907-14.
50. Louiset E, Stratakis CA, Perraudin V, et al. The paradoxical increase in cortisol secretion induced by dexamethasone in primary pigmented nodular adrenocortical disease involves a glucocorticoid receptor-mediated effect of dexamethasone on protein kinase A catalytic subunits. J Clin Endocrinol Metab 2009;94:2406-13.
51. Mete O, Asa SL. Morphological distinction of cortisol-producing and aldosterone-producing adrenal cortical adenomas: not only possible but a critical clinical responsibility. Histopathology 2012;60:1015-16.
52. Goh G, Scholl UI, Healy JM, et al. Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nat Genet 2014;46:613-17.
53. De Martino MC, Al Ghuzlan A, Aubert S, et al. Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. J Clin Endocrinol Metab 2013;98:4080-108.
54. Bourdeau I, Mackenzie-feder J, Lacroix A. Recent advances in adrenocortical carcinoma in adults. Curr Opin Endocrinol Diabetes Obes 2013;20:192-7.
55. Fassnacht M, Libé R, Kroiss M, et al. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 2011;7:323-35.
56. Lerario AM, Moraitis A, Hammer GD. Genetics and epigenetics of adrenocortical tumors. Mol Cell Endocrinol 2014;386:67-84.
57. Lacroix A. Approach to the patient with adrenocortical carcinoma. J Clin Endocrinol Metab 2010;95:4812-22.
58. Papotti M, Duregon E, Volante M, et al. Pathology of the adrenal cortex: a reappraisal of the past 25 years focusing on adrenal cortical tumors. Endocr Pathol 2014;25:35-48.
59. DeLellis RA, ed. Pathology & genetics: tumours of endocrine organs. Vol. 8. IARC, 2004.
60. Papotti M, Libè R, Duregon E, et al. The Weiss score and beyond-histopathology for adrenocortical carcinoma. Horm Cancer 2011;2:333-40.
61. Volante M, Bollito E, Sperone P, et al. Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology 2009;55:535-43.
62. Duregon E, Fassina A, Volante M, et al. The reticulin algorithm for adrenocortical tumor diagnosis: a multicentric validation study on 245 unpublished cases. Am J Surg Pathol 2013;37:1433-40.
63. De Reyniès A, Assié G, Rickman DS, et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 2009;27:1108-15.
64. Espiard S, Ragazzon B, Bertherat J. Protein kinase A alterations in adrenocortical tumors. Horm Metab Res 2014.
65. Di Dalmazi G, Kisker C, Calebiro D, et al. Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing's syndrome: a European multicentric study. J Clin Endocrinol Metab 2014;99:E2093-100.
66. Nakajima Y, Okamura T, Gohko T, et al. Somatic mutations of the catalytic subunit of cyclic AMP-dependent protein kinase (PRKACA) gene in Japanese patients with several adrenal adenomas secreting cortisol [Rapid Communication]. Endocr J 2014.
67. Sato Y, Maekawa S, Ishii R, et al. Recurrent somatic mutations underlie corticotropin-independent Cushing's syndrome. Science 2014;344:917-20.
68. Cao Y, He M, Gao Z, et al. Activating hotspot L205R mutation in PRKACA and adrenal Cushing's syndrome. Science 2014;344:913-17.
69. Beuschlein F, Fassnacht M, Assié G, et al. Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. N Engl J Med 2014;370:1019-28.
70. Kirschner LS. Medicine. A unified cause for adrenal Cushing's syndrome. Science 2014;344:804-5.
71. Giordano TJ. Genetics: Pinpointing a hotspot in adrenal Cushing syndrome. Nat Rev Endocrinol 2014;10:447-8.
72. Sargent J. Neuroendocrine cancer. An activating hotspot mutation in PRKACA provides clues for adrenal Cushing syndrome therapeutics. Nat Rev Endocrinol 2014;10:311.
73. De Joussineau C, Sahut-Barnola I, Levy I, et al. The cAMP pathway and the control of adrenocortical development and growth. Mol Cell Endocrinol 2012;351:28-36.
74. Yu B, Ragazzon B, Rizk-Rabin M, et al. Protein kinase A alterations in endocrine tumors. Horm Metab Res 2012;44:741-8.
75. Wilmot Roussel H, Vezzosi D, Rizk-Rabin M, et al. Identification of gene expression profiles associated with cortisol secretion in adrenocortical adenomas. J Clin Endocrinol Metab 2013;98:E1109-21.
76. Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000;26:89-92.
77. Azevedo MF, Faucz FR, Bimpaki E, et al. Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev 2014;35:195-233.
78. Vezzosi D, Libé R, Baudry C, et al. Phosphodiesterase 11A (PDE11A) gene defects in patients with ACTH-independent macronodular adrenal hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of bilateral adrenal tumors. J Clin Endocrinol Metab 2012;97:E2063-9.
79. Rothenbuhler A, Horvath A, Libé R, et al. Identification of novel genetic variants in phosphodiesterase 8B (PDE8B), a cAMP-specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours. Clin Endocrinol (Oxf) 2012;77:195-9.
80. Horvath A, Stratakis CA. Unravelling the molecular basis of micronodular adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes 2008;15:227-33.
81. Horvath A, Boikos S, Giatzakis C, et al. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet 2006;38:794-800.
82. Gagliardi L, Schreiber AW, Hahn CN, et al. ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab 2014;99:E1784-92.
83. Alencar GA, Lerario AM, Nishi MY, et al. ARMC5 mutations are a frequent cause of primary macronodular adrenal hyperplasia. J Clin Endocrinol Metab 2014;99: E1501-9.
84. Faucz FR, Zilbermint M, Lodish MB, et al. Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation. J Clin Endocrinol Metab 2014;99:E1113-19.
85. Assié G, Libé R, Espiard S, et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med 2013;369:2105-14.
86. Lacroix A. Heredity and cortisol regulation in bilateral macronodular adrenal hyperplasia. N Engl J Med 2013;369:2147-9.
87. Assié G, Letouzé E, Fassnacht M, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 2014;46:607-12.
88. Bonnet S, Gaujoux S, Launay P, et al. Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and-nonsecreting tumors. J Clin Endocrinol Metab 2011;96:E419-26.
89. Assié G, Jouinot A, Bertherat J. The 'omics' of adrenocortical tumours for personalized medicine. Nat Rev Endocrinol 2014;10:215-28.
90. Berthon A, Sahut-barnola I, Lambert-langlais S, et al. Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum Mol Genet 2010;19:1561-76.
91. Drelon C, Berthon A, Val P. Adrenocortical cancer and IGF2: is the game over or our experimental models limited? J Clin Endocrinol Metab 2013;98: 505-7.
92. Lacroix A, Bourdeau I, Lampron A, et al. Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction. Clin Endocrinol (Oxf) 2010;73:1-15.
93. Schteingart DE. The clinical spectrum of adrenocortical hyperplasia. Curr Opin Endocrinol Diabetes Obes 2012;19:176-82.
94. Elbelt U, Trovato A, Kloth M, et al. Molecular and clinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germline and somatic mutations are associated with both primary macronodular adrenal hyperplasia and meningioma. J Clin Endocrinol Metab 2014:jc20142648.
95. Carney JA, Stratakis CA, Young WF. Adrenal cortical adenoma: the fourth component of the Carney triad and an association with subclinical Cushing syndrome. Am J Surg Pathol 2013;37:1140-9.
96. Berthon A, Drelon C, Ragazzon B, et al. WNT/β-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. Hum Mol Genet 2014;23:889-905.
97. Ragazzon B, Libé R, Assié G, et al. Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas. Eur J Endocrinol 2014;170:385-91.
98. Stratakis CA. Adrenal cancer in 2013: Time to individualize treatment for adrenocortical cancer? Nat Rev Endocrinol 2014;10:76-8.
99. Ronchi CL, Sbiera S, Leich E, et al. Single nucleotide polymorphism array profiling of adrenocortical tumors-evidence for an adenoma carcinoma sequence?. PLoS ONE 2013;8:e73959.
100. Lila AR, Gopal RA, Acharya SV, et al. Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. Endocr Pract 2010;16:968-76.
101. Colao A, Petersenn S, Newell-price J, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 2012;366:914-24.
102. Fleseriu M, Biller BM, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012;97:2039-49.
103. Terzolo M, Zaggia B, Allasino B, et al. Practical treatment using mitotane for adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes 2014;21:159-65.
104. Tinat J, Bougeard G, Baert-desurmont S, et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 2009;27:e108-9.
105. Gomez-Sanchez CE. Channels and pumps in aldosterone-producing adenomas. J Clin Endocrinol Metab 2014;99:1152-6.